Clinical benefits of granulocyte colony-stimulating factor therapy after hematopoietic stem cell transplant in children: Results of a prospective randomized trial

Sandro Dallorso, Roberto Rodelli, Chiara Messina, Andrea Pession, Giovanna Giorgiani, Franca Fagioli, Franco Locatelli, Carla Manzitti, Adriana Balduzzi, Arcangelo Prete, Simone Cesaro, Elena Vassallo, Edoardo Lanino, Giorgio Dini

Research output: Contribution to journalArticle

Abstract

Background and Objectives. Hematopoietic stem cell transplantation (HSCT) is associated with profound neutropenia and significant morbidity and mortality. To evaluate the safety and efficacy of non-glycosylated recombinant human granulocyte colony-stimulating factor (rHuG-CSF) in accelerating myeloid recovery and its influence on infections, supportive therapy, and transplant-related mortality we carried out a randomized study in pediatric patients receiving HSCT. Design and Methods. Two hundred and twenty-one consecutive children, recipients of an allogeneic or autologous bone marrow (BM) or peripheral blood progenitor cell (PBPC) transplant, were randomized to either receive rHuG-CSF 10 ug/kg (n=110) or not (n=111) Results. Myeloid engraftment was faster in the treated arm (14 vs 20 days, p=0.0001). Neutrophil recovery was accelerated both in the BM subgroups (allogeneic and autologous, p=0.002) and in the PBPC group (p=0.0005). All the other evaluated variables showed an advantage in favor of rHuG-CSF treated patients that was significant for platelet transfusion independence and time to discharge (p=0.02 and p=0.04, respectively) only in the BM subgroup. Interpretation and Conclusions. We conclude that faster neutrophil recovery in BM recipients receiving rHuG-CSF led to clinical benefits, while, in the PBPC subgroup, it did not translate into clinical advantages.

Original languageEnglish
Pages (from-to)1274-1280
Number of pages7
JournalHaematologica
Volume87
Issue number12
Publication statusPublished - Dec 1 2002

Fingerprint

Granulocyte Colony-Stimulating Factor
Hematopoietic Stem Cells
Bone Marrow
Transplants
Blood Cells
Stem Cells
Hematopoietic Stem Cell Transplantation
Neutrophils
Platelet Transfusion
Mortality
Therapeutics
Neutropenia
Arm
Pediatrics
Morbidity
Safety
Infection

Keywords

  • Bone marrow transplantation
  • Children
  • RHu G-CSF

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical benefits of granulocyte colony-stimulating factor therapy after hematopoietic stem cell transplant in children : Results of a prospective randomized trial. / Dallorso, Sandro; Rodelli, Roberto; Messina, Chiara; Pession, Andrea; Giorgiani, Giovanna; Fagioli, Franca; Locatelli, Franco; Manzitti, Carla; Balduzzi, Adriana; Prete, Arcangelo; Cesaro, Simone; Vassallo, Elena; Lanino, Edoardo; Dini, Giorgio.

In: Haematologica, Vol. 87, No. 12, 01.12.2002, p. 1274-1280.

Research output: Contribution to journalArticle

Dallorso, Sandro ; Rodelli, Roberto ; Messina, Chiara ; Pession, Andrea ; Giorgiani, Giovanna ; Fagioli, Franca ; Locatelli, Franco ; Manzitti, Carla ; Balduzzi, Adriana ; Prete, Arcangelo ; Cesaro, Simone ; Vassallo, Elena ; Lanino, Edoardo ; Dini, Giorgio. / Clinical benefits of granulocyte colony-stimulating factor therapy after hematopoietic stem cell transplant in children : Results of a prospective randomized trial. In: Haematologica. 2002 ; Vol. 87, No. 12. pp. 1274-1280.
@article{ce70558da8e04ae783e9ec1d9ab0062f,
title = "Clinical benefits of granulocyte colony-stimulating factor therapy after hematopoietic stem cell transplant in children: Results of a prospective randomized trial",
abstract = "Background and Objectives. Hematopoietic stem cell transplantation (HSCT) is associated with profound neutropenia and significant morbidity and mortality. To evaluate the safety and efficacy of non-glycosylated recombinant human granulocyte colony-stimulating factor (rHuG-CSF) in accelerating myeloid recovery and its influence on infections, supportive therapy, and transplant-related mortality we carried out a randomized study in pediatric patients receiving HSCT. Design and Methods. Two hundred and twenty-one consecutive children, recipients of an allogeneic or autologous bone marrow (BM) or peripheral blood progenitor cell (PBPC) transplant, were randomized to either receive rHuG-CSF 10 ug/kg (n=110) or not (n=111) Results. Myeloid engraftment was faster in the treated arm (14 vs 20 days, p=0.0001). Neutrophil recovery was accelerated both in the BM subgroups (allogeneic and autologous, p=0.002) and in the PBPC group (p=0.0005). All the other evaluated variables showed an advantage in favor of rHuG-CSF treated patients that was significant for platelet transfusion independence and time to discharge (p=0.02 and p=0.04, respectively) only in the BM subgroup. Interpretation and Conclusions. We conclude that faster neutrophil recovery in BM recipients receiving rHuG-CSF led to clinical benefits, while, in the PBPC subgroup, it did not translate into clinical advantages.",
keywords = "Bone marrow transplantation, Children, RHu G-CSF",
author = "Sandro Dallorso and Roberto Rodelli and Chiara Messina and Andrea Pession and Giovanna Giorgiani and Franca Fagioli and Franco Locatelli and Carla Manzitti and Adriana Balduzzi and Arcangelo Prete and Simone Cesaro and Elena Vassallo and Edoardo Lanino and Giorgio Dini",
year = "2002",
month = "12",
day = "1",
language = "English",
volume = "87",
pages = "1274--1280",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "12",

}

TY - JOUR

T1 - Clinical benefits of granulocyte colony-stimulating factor therapy after hematopoietic stem cell transplant in children

T2 - Results of a prospective randomized trial

AU - Dallorso, Sandro

AU - Rodelli, Roberto

AU - Messina, Chiara

AU - Pession, Andrea

AU - Giorgiani, Giovanna

AU - Fagioli, Franca

AU - Locatelli, Franco

AU - Manzitti, Carla

AU - Balduzzi, Adriana

AU - Prete, Arcangelo

AU - Cesaro, Simone

AU - Vassallo, Elena

AU - Lanino, Edoardo

AU - Dini, Giorgio

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Background and Objectives. Hematopoietic stem cell transplantation (HSCT) is associated with profound neutropenia and significant morbidity and mortality. To evaluate the safety and efficacy of non-glycosylated recombinant human granulocyte colony-stimulating factor (rHuG-CSF) in accelerating myeloid recovery and its influence on infections, supportive therapy, and transplant-related mortality we carried out a randomized study in pediatric patients receiving HSCT. Design and Methods. Two hundred and twenty-one consecutive children, recipients of an allogeneic or autologous bone marrow (BM) or peripheral blood progenitor cell (PBPC) transplant, were randomized to either receive rHuG-CSF 10 ug/kg (n=110) or not (n=111) Results. Myeloid engraftment was faster in the treated arm (14 vs 20 days, p=0.0001). Neutrophil recovery was accelerated both in the BM subgroups (allogeneic and autologous, p=0.002) and in the PBPC group (p=0.0005). All the other evaluated variables showed an advantage in favor of rHuG-CSF treated patients that was significant for platelet transfusion independence and time to discharge (p=0.02 and p=0.04, respectively) only in the BM subgroup. Interpretation and Conclusions. We conclude that faster neutrophil recovery in BM recipients receiving rHuG-CSF led to clinical benefits, while, in the PBPC subgroup, it did not translate into clinical advantages.

AB - Background and Objectives. Hematopoietic stem cell transplantation (HSCT) is associated with profound neutropenia and significant morbidity and mortality. To evaluate the safety and efficacy of non-glycosylated recombinant human granulocyte colony-stimulating factor (rHuG-CSF) in accelerating myeloid recovery and its influence on infections, supportive therapy, and transplant-related mortality we carried out a randomized study in pediatric patients receiving HSCT. Design and Methods. Two hundred and twenty-one consecutive children, recipients of an allogeneic or autologous bone marrow (BM) or peripheral blood progenitor cell (PBPC) transplant, were randomized to either receive rHuG-CSF 10 ug/kg (n=110) or not (n=111) Results. Myeloid engraftment was faster in the treated arm (14 vs 20 days, p=0.0001). Neutrophil recovery was accelerated both in the BM subgroups (allogeneic and autologous, p=0.002) and in the PBPC group (p=0.0005). All the other evaluated variables showed an advantage in favor of rHuG-CSF treated patients that was significant for platelet transfusion independence and time to discharge (p=0.02 and p=0.04, respectively) only in the BM subgroup. Interpretation and Conclusions. We conclude that faster neutrophil recovery in BM recipients receiving rHuG-CSF led to clinical benefits, while, in the PBPC subgroup, it did not translate into clinical advantages.

KW - Bone marrow transplantation

KW - Children

KW - RHu G-CSF

UR - http://www.scopus.com/inward/record.url?scp=12244275733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244275733&partnerID=8YFLogxK

M3 - Article

C2 - 12495901

AN - SCOPUS:12244275733

VL - 87

SP - 1274

EP - 1280

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 12

ER -